Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
NCT ID NCT02727803
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multiple myeloma. Researchers hope this approach will improve how long patients stay cancer-free and reduce the risk of graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Natural killer (NK) cells from cord blood, along with anti-thymocyte globulin and busulfan chemotherapy
- What this could lead to
- If successful, this approach could improve progression-free survival for patients with hard-to-treat blood cancers by using the patient's own immune cells to target remaining cancer cells after transplant.
- What could go wrong
- This is a mid-stage trial with only 100 participants, so results may not apply to everyone. There are risks from chemotherapy and transplant, including infection and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors